AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Chemotherapy-Induced Anemia Market Spotlight Report 2019: Pfizer’s Epogen Biosimilar Retacrit Launches at 33% Off in a US Market where Amgen’s Already Competitive - ResearchAndMarkets.com

December 2, 2019

DUBLIN--(BUSINESS WIRE)--Dec 2, 2019--

The “Market Spotlight: Chemotherapy-Induced Anemia” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Key Topics Covered:

1. Overview

2. Key Takeaways

3. Disease Background

4. Treatment

5. Epidemiology

6. Marketed Drugs

7. Pipeline Drugs

8. Key Upcoming Events

9. Key Regulatory Events

10. Probability of Success

11. Licensing and Asset Acquisition Deals

12. Revenue Opportunity

13. Clinical Trial Landscape

14. Bibliography

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/eh189l

View source version on businesswire.com:https://www.businesswire.com/news/home/20191202005828/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 12/02/2019 01:34 PM/DISC: 12/02/2019 01:34 PM

http://www.businesswire.com/news/home/20191202005828/en